Lyell Immunopharma Inc. has announced positive new clinical data from a multi-center Phase 1/2 trial of its LYL314 treatment for aggressive large B-cell lymphoma. The trial demonstrated an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting. Among those achieving a complete response, 71% remained in complete response for at least six months. The treatment, LYL314, is an autologous dual-targeting CD19/CD20 chimeric antigen receptor $(CAR)$ T-cell product candidate with Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA, aimed at relapsed and/or refractory large B-cell lymphoma. A pivotal single-arm PiNACLE trial is currently underway in CAR T-naïve patients. The clinical data will be presented on June 18, 2025, at the International Conference on Malignant Lymphoma in Lugano, Switzerland.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.